Bullboard - Stock Discussion Forum Pasithea Therapeutics Corp KTTA

Healthcare Biotechnology

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small... see more

Add To Watchlist

NDAQ:KTTA - Post Discussion

Pasithea Therapeutics Corp > Pasithea Therapeutics Announces Completion of Enrollment and

View:

Post by whytestocks on Jun 13, 2024 7:30pm

Pasithea Therapeutics Announces Completion of Enrollment and

BREAKING NEWS: $KTTA Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialMIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis typ...KTTA - Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial